FORM OF COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC.Protea Biosciences Group, Inc. • May 29th, 2015 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the three year anniversary of the Final Closing Date under the Subscription Agreement (the “Termination Date”) but not thereafter, to subscribe for and purchase from Protea Biosciences Group, Inc., a Delaware corporation (the “Company”), up to 7,500,000 shares (the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SUBSCRIPTION AGREEMENTSubscription Agreement • May 29th, 2015 • Protea Biosciences Group, Inc. • Pharmaceutical preparations • New York
SUBSCRIPTION AGREEMENT (this “Agreement”) made as of the last date set forth on the signature page hereof between Protea Biosciences Group, Inc., (the “Company”), and the undersigned (the “Subscriber”).
20% ORIGINAL ISSUE DISCOUNT UNSECURED CONVERTIBLE DEBENTURE DUE NOVEMBER 22, 2015Protea Biosciences Group, Inc. • May 29th, 2015 • Pharmaceutical preparations • New York
THIS 20% ORIGINAL ISSUE DISCOUNT UNSECURED CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued 20% Original Issue Discount Unsecured Convertible Debentures of Protea Biosciences Group, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 955 Hartman Run Road, Morgantown, WV 26507, designated as its 20% Original Issue Discount Unsecured Convertible Debenture due November 22, 2015 (this debenture, the “Debenture” and, collectively with the other debentures of such series, the “Debentures”).
